Secondary analysis of APHINITY (HER2+ early breast cancer): higher sTILs by manual, digital and AI scoring were linked to better invasive disease-free survival (HRs 0·41–0·93); pertuzumab benefit appeared greater at high sTILs (HRs 0·36–0·48).
Secondary analysisn = 4,262 tumour images
Lara González et al. Manual, digital, and AI tumour-infiltrating lymphocyte scoring: a secondary analysis of the APHINITY randomised trial